Base de dados : MEDLINE
Pesquisa : D02.455.426.392.368.242.888.777.500 [Categoria DeCS]
Referências encontradas : 171 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 18 ir para página                         

  1 / 171 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390506
[Au] Autor:Anzai M; Morikawa M; Okuno T; Umeda Y; Demura Y; Sonoda T; Yamaguchi M; Kanno K; Shiozaki K; Ameshima S; Akai M; Ishizuka T
[Ad] Endereço:Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Fukui.
[Ti] Título:Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer.
[So] Source:Medicine (Baltimore);96(51):e9320, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Nanoparticle albumin-bound paclitaxel (nab-PTX), which avoids toxicities associated with a vehicle used in solvent-based PTX, has already shown safety and efficacy in patients with non-small cell lung cancer (NSCLC). METHODS: A phase II study was performed to assess the safety and efficacy of nab-PTX monotherapy as second-line chemotherapy after cytotoxic anticancer drugs for previously treated advanced NSCLC. Thirty-two patients with advanced NSCLC who had previously undergone 1 regimen of cytotoxic anticancer drugs were enrolled. Nab-PTX was administered intravenously at a dose of 100 mg/m on days 1, 8, and 15 of a 28-day cycle. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and toxicity profile were evaluated. RESULTS: The ORR was 28.1%, the DCR was 71.9%, median PFS was 3.9 months (95% confidence interval [CI] 2.7-5.1 months), and median OS was 10.9 months (95% CI 9.5-12.3 months). The mean relative dose intensity of nab-PTX was 77%. Grade 3 or 4 neutropenia, and grade 3 febrile neutropenia were observed in 11 and 1 of 32 patients, respectively. As nonhematologic toxicities, grade 3 peripheral sensory neuropathy and pneumonitis were each observed in 2 of 32 patients. CONCLUSION: Nab-PTX is an active and well-tolerated regimen in patients with previously treated NSCLC.
[Mh] Termos MeSH primário: Paclitaxel Ligado a Albumina/uso terapêutico
Antineoplásicos/uso terapêutico
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico
Neoplasias Pulmonares/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Anemia/induzido quimicamente
Carcinoma Pulmonar de Células não Pequenas/mortalidade
Feminino
Seres Humanos
Japão/epidemiologia
Neoplasias Pulmonares/mortalidade
Masculino
Meia-Idade
Neutropenia/induzido quimicamente
Doenças do Sistema Nervoso Periférico/induzido quimicamente
Pneumonia/induzido quimicamente
Terapia de Salvação
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Albumin-Bound Paclitaxel); 0 (Antineoplastic Agents)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009320


  2 / 171 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29277798
[Au] Autor:Takashima T; Kawajiri H; Nishimori T; Tei S; Nishimura S; Yamagata S; Tokunaga S; Mizuyama Y; Sunami T; Tezuka K; Ikeda K; Ogawa Y; Kashiwagi S; Noda S; Onoda N; Ishikawa T; Kudoh S; Takada M; Hirakawa K; Ohira M
[Ad] Endereço:Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan tsutomu-@rd5.so-net.ne.jp.
[Ti] Título:Safety and Efficacy of Low-dose Nanoparticle Albumin-bound Paclitaxel for HER2-negative Metastatic Breast Cancer.
[So] Source:Anticancer Res;38(1):379-383, 2018 01.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: Nab-paclitaxel (nab-PTX) is an albumin-bound paclitaxel formulation. Although nab-PTX has shown superior efficacy compared to conventional paclitaxel (PTX) in metastatic breast cancer (MBC), chemotherapy-induced peripheral neuropathy (CIPN) was more frequently observed in nab-PTX. In this study, we aimed to estimate the feasibility of the nab-PTX 175 mg/m /3weeks regimen. PATIENTS AND METHODS: Patients having metastatic or inoperable HER2-negative breast cancer received 175 mg/m of nab-PTX every three weeks. The primary endpoint was safety and the secondary endpoints were response and survival. RESULTS: Seventeen patients were enrolled with a median age of 64 years. Ten patients had estrogen receptor positive disease and seven had triple-negative disease. CIPN was observed in seven patients (41%) however, grade 3 CIPN was only seen in one patient (6%). Objective response rate was 41% and progression-free survival was 23 weeks. CONCLUSION: Nab-PTX 175 mg/m /3wks regimen has a good safety profile and less frequent CIPN. This regimen can contribute to the strategy of MBC treatment.
[Mh] Termos MeSH primário: Paclitaxel Ligado a Albumina/efeitos adversos
Paclitaxel Ligado a Albumina/uso terapêutico
Albuminas/efeitos adversos
Albuminas/uso terapêutico
Antineoplásicos/uso terapêutico
Paclitaxel/efeitos adversos
Paclitaxel/uso terapêutico
Receptor ErbB-2/metabolismo
Neoplasias de Mama Triplo Negativas/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Antineoplásicos/efeitos adversos
Intervalo Livre de Doença
Feminino
Seres Humanos
Meia-Idade
Receptores Estrogênicos/metabolismo
Neoplasias de Mama Triplo Negativas/metabolismo
Neoplasias de Mama Triplo Negativas/patologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (130-nm albumin-bound paclitaxel); 0 (Albumin-Bound Paclitaxel); 0 (Albumins); 0 (Antineoplastic Agents); 0 (Receptors, Estrogen); EC 2.7.10.1 (ERBB2 protein, human); EC 2.7.10.1 (Receptor, ErbB-2); P88XT4IS4D (Paclitaxel)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171227
[St] Status:MEDLINE


  3 / 171 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29061836
[Au] Autor:Matsui A; Tatibana A; Suzuki N; Hirata M; Oishi Y; Hamaguchi Y; Murata Y; Nagayama A; Iwata Y; Okamoto Y
[Ad] Endereço:Department of Breast Surgery, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan matsuiakira@kankakuki.go.jp.
[Ti] Título:Evaluation of Efficacy and Safety of Upfront Weekly Nanoparticle Albumin-bound Paclitaxel for HER2-negative Breast Cancer.
[So] Source:Anticancer Res;37(11):6481-6488, 2017 11.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Taxanes are among the key drugs for breast cancer treatment. This study aimed to evaluate the efficacy of upfront weekly nanoparticle albumin-bound paclitaxel (Nab-PTX; 100 mg/m ) for human epidermal growth factor 2 (HER2)-negative breast cancer. PATIENTS AND METHODS: Patients with stage II to IV breast cancer received 12 cycles of weekly 100 mg/m Nab-PTX as first-line treatment. Preoperative chemotherapy with anthracyclines after Nab-PTX was recommended. RESULTS: From 2012 to 2014, we enrolled 66 patients. The overall response rate after Nab-PTX was 59.1% [95% confidence interval(CI)=47.2% to 71.0%), 63.6% in those with hormone receptor-positive tumors, and 36.4% in those with triple-negative tumors. The pathological complete response rate at surgery was 15% (95% CI=6.1% to 24.4%). Toxicity analysis showed grade 2 peripheral neuropathy in 38 patients (57.6%), grade 2/3 leukocytopenia in 29 (43.9%) and grade 2/3 liver dysfunction in five (7.5%). CONCLUSION: Weekly neoadjuvant Nab-PTX at 100 mg/m led to good response rates (59.1%) and was well tolerated.
[Mh] Termos MeSH primário: Paclitaxel Ligado a Albumina/efeitos adversos
Antineoplásicos/efeitos adversos
Neoplasias da Mama/tratamento farmacológico
Receptor ErbB-2/genética
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Antraciclinas/uso terapêutico
Antineoplásicos/administração & dosagem
Neoplasias da Mama/genética
Neoplasias da Mama/patologia
Esquema de Medicação
Feminino
Seres Humanos
Meia-Idade
Terapia Neoadjuvante
Estadiamento de Neoplasias
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Albumin-Bound Paclitaxel); 0 (Anthracyclines); 0 (Antineoplastic Agents); EC 2.7.10.1 (ERBB2 protein, human); EC 2.7.10.1 (Receptor, ErbB-2)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171026
[Lr] Data última revisão:
171026
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171025
[St] Status:MEDLINE


  4 / 171 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28858103
[Au] Autor:Naito Y; Tamiya A; Tamiya M; Kimura Y; Hamaguchi M; Saijo N; Kanazu M; Tokura S; Shiroyama T; Morisita N; Omachi N; Suzuki H; Okamoto N; Okishio K; Hirashima T; Atagi S
[Ad] Endereço:aDepartment of Internal Medicine, National Hospital Organization Kinki-chuo Chest Medical Center bDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Suita City cDepartment of Thoracic Oncology, Osaka Prefectural Hospital Organization Osaka Habikino Medical Center, Habikino City dDepartment of Respiratory Internal Medicine, Osaka International Cancer Institute eDepartment of Thoracic Oncology, National Hospital Organization Toneyama National Hospital, Toyonaka City fDepartment of Thoracic Oncology, National Hospital Organization Kinki-chuo Chest Medical Center, Sakai City, Osaka, Japan.
[Ti] Título:Efficacy of nanoparticle albumin-bound paclitaxel regimens for relapsed small cell lung cancer: A retrospective analysis.
[So] Source:Medicine (Baltimore);96(35):e7884, 2017 Sep.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Although small cell lung cancer (SCLC) is initially sensitive to chemotherapy, it recurs in most cases. Standard regimens for salvage chemotherapy have not been established, and the prognosis of relapsed SCLC remains poor. In the present study, we investigated the clinical efficacy and safety of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) regimens for the treatment of relapsed SCLC.In this retrospective multicenter analysis, 14 patients (3 women and 11 men; median age 71 years) with relapsed SCLC received nab-paclitaxel alone or in combination with carboplatin between February 2013 and July 2014. The safety and efficacy of the regimens were evaluated.The response rates, disease control rates, and median overall survival for the total patient population were 36%, 64%, and 7.8 months, respectively. Response rates, disease control rates, and the median overall survival were 11%, 44%, and 4 months, respectively, in the monotherapy group; and 80%, 100%, and 10.6 months, respectively, in the combination therapy group. The most common adverse events were hematological toxicities such as neutropenia and anemia. Severe neutropenia appeared in some patients, although it was resolved by treatment in all. The most common nonhematological toxicity was anorexia (64%), followed by neurotoxicity and constipation. All nonhematological toxicities were mild and manageable.Our results suggest that chemotherapy with nab-paclitaxel regimens for relapsed SCLC exhibits moderate clinical efficacy and is well-tolerated. Further clinical trials in relapsed SCLC patients are warranted.
[Mh] Termos MeSH primário: Paclitaxel Ligado a Albumina/uso terapêutico
Antineoplásicos/uso terapêutico
Neoplasias Pulmonares/tratamento farmacológico
Carcinoma de Pequenas Células do Pulmão/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Paclitaxel Ligado a Albumina/administração & dosagem
Paclitaxel Ligado a Albumina/efeitos adversos
Antineoplásicos/administração & dosagem
Antineoplásicos/efeitos adversos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Carboplatina/administração & dosagem
Feminino
Seres Humanos
Neoplasias Pulmonares/mortalidade
Masculino
Meia-Idade
Recidiva Local de Neoplasia
Estudos Retrospectivos
Carcinoma de Pequenas Células do Pulmão/mortalidade
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Albumin-Bound Paclitaxel); 0 (Antineoplastic Agents); BG3F62OND5 (Carboplatin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170925
[Lr] Data última revisão:
170925
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170901
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000007884


  5 / 171 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28790265
[Au] Autor:Ito T; Deguchi K; Yoshii K; Kashii M
[Ad] Endereço:Dept. of Surgery, Rakuwakai Marutamachi Hospital.
[Ti] Título:[A Case of Cystoid Macular Edema Secondary to Albumin-Bound Paclitaxel Therapy].
[So] Source:Gan To Kagaku Ryoho;44(7):599-602, 2017 Jul.
[Is] ISSN:0385-0684
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:A 73-year-old woman diagnosed with unresectable pancreatic cancer received weekly gemcitabine(GEM)plus albuminbound paclitaxel(nab-PTX)therapy. Four months after nab-PTX therapy was initiated, she presented with a rapidly decreasing vision in her left eye at an ophthalmology clinic. On admission, her visual acuity was decreased, and optical coherence tomography(OCT)revealed a cystoid macular edema(CME)only in her left eye. She discontinued the nab-PTX therapy immediately. Her visual acuity improved on follow-up 6 months later. The CME finding on OCT was reduced but not completely resolved. CME is a rare adverse event induced by nab-PTX therapy, with only 14 cases reported since 2008. In most of the reported cases, the patients had breast cancer, and this is the first reported case of CME in a patient with pancreatic cancer. The time to CME onset from starting nab-PTX therapy was reported to range from3 to 30months, but the predilection time has not been clarified. Many reports indicated that symptoms improved in a short period after discontinuation of nab-PTX therapy, but effective treatment was not established, except discontinuation of nab-PTX therapy. In daily medical treatment, the incongruity of the ophthalmologic domain should be confirmed for early detection of CME.
[Mh] Termos MeSH primário: Paclitaxel Ligado a Albumina/efeitos adversos
Antineoplásicos/efeitos adversos
Edema Macular/induzido quimicamente
Neoplasias Pancreáticas/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Paclitaxel Ligado a Albumina/uso terapêutico
Antineoplásicos/uso terapêutico
Feminino
Seres Humanos
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Albumin-Bound Paclitaxel); 0 (Antineoplastic Agents)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170810
[St] Status:MEDLINE


  6 / 171 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28698445
[Au] Autor:Uchiyama M; Goto T; Ueno M; Kakimoto H; Mashima K; Ikari Y; Takamatsu Y; Ogata K; Kamimura H
[Ad] Endereço:Dept. of Pharmacy, Fukuoka University Hospital.
[Ti] Título:[A Case of Albumin-Bound Paclitaxel-Induced Peripheral Neuropathy without Exacerbation].
[So] Source:Gan To Kagaku Ryoho;44(6):517-519, 2017 Jun.
[Is] ISSN:0385-0684
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:Albumin-bound paclitaxel(nab-PTX)-associated neuropathy decreases the quality of life of cancer patients and leads to dose modification, discontinuation of chemotherapy, and occasionally dose-limiting toxicity. In the present case study, a 92- year-old female patient with peritoneal cancer of carcinomatous peritonitis and carcinomatous ascites was treated with carboplatin plus nab-PTX every 4 weeks as first-line chemotherapy, and a good response was achieved following 4 cycles of this regimen. However, the patient developed Grade 3 peripheral neuropathy and stopped the therapy. As a result, the peripheral neuropathy gradually improved. After 1 year, ascites appeared, and tumor marker(CA125)levels increased. We tried an 8-h infusion of nab-PTX to avoid peripheralneuropathy. After 4 cycles, a positive response was achieved without exacerbation of the peripheralneuropathy. Administering nab-PTX over shorter periods of time has generally led to increased peripheral neuropathy. The severity of peripheralneuropathy can be reduced with a longer infusion time.
[Mh] Termos MeSH primário: Paclitaxel Ligado a Albumina/efeitos adversos
Doenças do Sistema Nervoso Periférico/induzido quimicamente
Neoplasias Peritoneais/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso de 80 Anos ou mais
Paclitaxel Ligado a Albumina/administração & dosagem
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Carboplatina/administração & dosagem
Feminino
Seres Humanos
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Albumin-Bound Paclitaxel); BG3F62OND5 (Carboplatin)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170915
[Lr] Data última revisão:
170915
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170713
[St] Status:MEDLINE


  7 / 171 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28687352
[Au] Autor:Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
[Ad] Endereço:Department of Nanomedicine, Houston Methodist Research Institute, 6700 Bertner Ave., Houston, TX 77030, USA.
[Ti] Título:Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
[So] Source:Cancer Lett;403:296-304, 2017 Sep 10.
[Is] ISSN:1872-7980
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:The mechanism for improved therapeutic efficacy of the combination therapy with nanoparticle albumin-bound paclitaxel (nAb-PTX) and gemcitabine (gem) for pancreatic ductal adenocarcinoma (PDAC) has been ascribed to enhanced gem transport by nAb-PTX. Here, we used an orthotopic mouse model of gem-resistant human PDAC in which increasing gem transport would not improve the efficacy, thus revealing the importance of nAb-PTX transport. We aimed to evaluate therapeutic outcomes and transport of nAb-PTX to PDAC as a result of (1) encapsulating nAb-PTX in multistage nanovectors (MSV); (2) effect of gem on caveolin-1 expression. Treatment with MSV/nAb-PTX + gem was highly efficient in prolonging animal survival in comparison to other therapeutic regimens. MSV/nAb-PTX + gem also caused a substantial increase in tumor PTX accumulation, significantly reduced tumor growth and tumor cell proliferation, and increased apoptosis. Moreover, gem enhanced caveolin-1 expression in vitro and in vivo, thereby improving transport of nAb-PTX to PDAC. This data was confirmed by analysis of PDACs from patients who received gem-based neo-adjuvant chemotherapy. In conclusion, we found that nAb-PTX treatment of gem-resistant PDAC can be enhanced by (1) gem through up-regulation of caveolin-1 and (2) MSV through increasing accumulation of nAb-PTX in the tumor.
[Mh] Termos MeSH primário: Paclitaxel Ligado a Albumina/metabolismo
Antimetabólitos Antineoplásicos/farmacologia
Antineoplásicos Fitogênicos/farmacologia
Carcinoma Ductal Pancreático/tratamento farmacológico
Desoxicitidina/análogos & derivados
Portadores de Fármacos
Resistência a Medicamentos Antineoplásicos
Nanopartículas
Neoplasias Pancreáticas/tratamento farmacológico
[Mh] Termos MeSH secundário: Paclitaxel Ligado a Albumina/química
Animais
Antineoplásicos Fitogênicos/química
Antineoplásicos Fitogênicos/metabolismo
Apoptose/efeitos dos fármacos
Carcinoma Ductal Pancreático/metabolismo
Carcinoma Ductal Pancreático/patologia
Caveolina 1/metabolismo
Linhagem Celular Tumoral
Proliferação Celular/efeitos dos fármacos
Desoxicitidina/farmacologia
Composição de Medicamentos
Seres Humanos
Masculino
Camundongos Nus
Neoplasias Pancreáticas/metabolismo
Neoplasias Pancreáticas/patologia
Fatores de Tempo
Carga Tumoral/efeitos dos fármacos
Regulação para Cima
Ensaios Antitumorais Modelo de Xenoenxerto
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Albumin-Bound Paclitaxel); 0 (Antimetabolites, Antineoplastic); 0 (Antineoplastic Agents, Phytogenic); 0 (CAV1 protein, human); 0 (Caveolin 1); 0 (Drug Carriers); 0W860991D6 (Deoxycytidine); B76N6SBZ8R (gemcitabine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170709
[St] Status:MEDLINE


  8 / 171 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28280335
[Au] Autor:Zhao M; Li H; Ma Y; Gong H; Yang S; Fang Q; Hu Z
[Ad] Endereço:Chinese Academy of Sciences Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, People's Republic of China.
[Ti] Título:Nanoparticle abraxane possesses impaired proliferation in A549 cells due to the underexpression of glucosamine 6-phosphate N-acetyltransferase 1 (GNPNAT1/GNA1).
[So] Source:Int J Nanomedicine;12:1685-1697, 2017.
[Is] ISSN:1178-2013
[Cp] País de publicação:New Zealand
[La] Idioma:eng
[Ab] Resumo:Abraxane (Abr), a US Food and Drug Administration-approved albumin-bound nanoparticle applied for the treatment of non-small-cell lung cancer, has been reported to be more effective than paclitaxel (PTX). To further understand the molecular mechanisms that produce this superior drug efficacy of Abr, a quantitative proteomic approach has been applied to investigate the global protein expression profiles of lung cancer cell A549 treated with Abr and PTX. Only one protein, namely, glucosamine 6-phosphate N-acetyltransferase 1 (GNA1), showed significant differential expression ( <0.05) in the cutoff of 2.0 fold, suggesting that Abr can be used safely as a substitute for PTX. GNA1 is a key enzyme in the biosynthesis of uridine diphosphate-N-acetylglucosamine, which is an important donor substrate for N-linked glycosylation and has several important functions such as embryonic development and growth. Albumin plays a major role in the regulation of this protein. In summary, this study first shows that the superior drug effect of Abr is mainly due to the downregulation of GNA1, which causes proliferative delay and cell adhesion defect. It is also noteworthy that the deficiency of GNA1 might reduce insulin secretion which correlates with type 2 diabetes.
[Mh] Termos MeSH primário: Paclitaxel Ligado a Albumina/farmacologia
Carcinoma Pulmonar de Células não Pequenas/patologia
Glucosamina 6-Fosfato N-Acetiltransferase/metabolismo
Neoplasias Pulmonares/patologia
Nanopartículas/química
[Mh] Termos MeSH secundário: Células A549
Actinas/metabolismo
Apoptose/efeitos dos fármacos
Western Blotting
Adesão Celular/efeitos dos fármacos
Proliferação Celular/efeitos dos fármacos
Sobrevivência Celular/efeitos dos fármacos
Cromatografia Líquida
Seres Humanos
Marcação por Isótopo
Modelos Biológicos
Paclitaxel/farmacologia
Polimerização
Proteômica
Reprodutibilidade dos Testes
Espectrometria de Massas em Tandem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Actins); 0 (Albumin-Bound Paclitaxel); EC 2.3.1.4 (Glucosamine 6-Phosphate N-Acetyltransferase); P88XT4IS4D (Paclitaxel)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170508
[Lr] Data última revisão:
170508
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170311
[St] Status:MEDLINE
[do] DOI:10.2147/IJN.S129976


  9 / 171 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28078561
[Au] Autor:Ley J; Wildes TM; Daly K; Oppelt P; Adkins D
[Ad] Endereço:Division of Medical Oncology, Department of Internal Medicine, Washington University School of Medicine, 660 South Euclid, Campus Box 8056, St. Louis, MO, 63110, USA.
[Ti] Título:Clinical benefit of nanoparticle albumin-bound-paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma resistant to cremophor-based paclitaxel or docetaxel.
[So] Source:Med Oncol;34(2):28, 2017 Feb.
[Is] ISSN:1559-131X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The clinical benefit of nab-paclitaxel monotherapy for recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC) that progressed on other taxanes (cremophor-based paclitaxel or docetaxel) is unknown. A retrospective analysis of patients treated at a single institution with nab-paclitaxel for taxane-resistant RM-HNSCC. The exploratory hypothesis was that nab-paclitaxel would result in clinical benefit (tumor response) in patients with taxane-resistant RM-HNSCC. Twelve patients who were treated with nab-paclitaxel monotherapy for taxane-resistant RM-HNSCC and met all eligibility criteria were identified. The majority of patients (n = 9; 75%) received three or more lines of therapy for RM-HNSCC. All patients had platin-resistant, and ten patients (83%) had cetuximab-resistant disease. Patients had RM-HNSCC that progressed on cremophor-based paclitaxel (8), docetaxel (1), or both (3). With prior taxane, the best tumor response was partial (PR) in 4 patients (33%), stable (SD) in 3 (25%), and progression in 5 (42%). The median time-to-progression (TTP) with prior taxane was 1.7 (range 0.7-9.0) months. The median interval from last dose of taxane to first dose of nab-paclitaxel was 3 (0.7-31.3) months. With nab-paclitaxel, tumor response occurred in two patients (17%; PR in both) and disease control (PR and SD) occurred in five (42%). Median TTP with nab-paclitaxel was 2.1 months (range 0.6-6.2), and median overall survival was 4.9 months (range 1.9-13.5). nab-Paclitaxel provided clinical benefit in some patients with taxane-resistant RM-HNSCC. The median TTP with nab-paclitaxel and with prior taxane were similar. This exploratory observation warrants further investigation in prospective studies.
[Mh] Termos MeSH primário: Paclitaxel Ligado a Albumina/uso terapêutico
Carcinoma de Células Escamosas/tratamento farmacológico
Neoplasias de Cabeça e Pescoço/tratamento farmacológico
Recidiva Local de Neoplasia/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Antineoplásicos/administração & dosagem
Antineoplásicos/farmacologia
Antineoplásicos/uso terapêutico
Carcinoma de Células Escamosas/diagnóstico por imagem
Carcinoma de Células Escamosas/patologia
Resistência a Medicamentos Antineoplásicos
Feminino
Neoplasias de Cabeça e Pescoço/diagnóstico por imagem
Neoplasias de Cabeça e Pescoço/patologia
Seres Humanos
Masculino
Meia-Idade
Metástase Neoplásica
Recidiva Local de Neoplasia/patologia
Paclitaxel/administração & dosagem
Paclitaxel/farmacologia
Polietilenoglicóis/administração & dosagem
Estudos Retrospectivos
Taxoides/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Albumin-Bound Paclitaxel); 0 (Antineoplastic Agents); 0 (Taxoids); 15H5577CQD (docetaxel); 30IQX730WE (Polyethylene Glycols); 39279-69-1 (cremophor); P88XT4IS4D (Paclitaxel)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:171108
[Lr] Data última revisão:
171108
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170113
[St] Status:MEDLINE
[do] DOI:10.1007/s12032-017-0884-7


  10 / 171 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28069389
[Au] Autor:Ruttala HB; Ramasamy T; Shin BS; Choi HG; Yong CS; Kim JO
[Ad] Endereço:College of Pharmacy, Yeungnam University, 280 Daehak-Ro, Gyeongsan 712-749, South Korea.
[Ti] Título:Layer-by-layer assembly of hierarchical nanoarchitectures to enhance the systemic performance of nanoparticle albumin-bound paclitaxel.
[So] Source:Int J Pharm;519(1-2):11-21, 2017 Mar 15.
[Is] ISSN:1873-3476
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Although protein-bound paclitaxel (PTX, Abraxane ) has been established as a standard PTX-based therapy against multiple cancers, its clinical success is limited by unfavorable pharmacokinetics, suboptimal biodistribution, and acute toxicities. In the present study, we aimed to apply the principles of a layer-by-layer (LbL) technique to improve the poor colloidal stability and pharmacokinetic pattern of nanoparticle albumin-bound paclitaxel (nab-PTX). LbL-based nab-PTX was successfully fabricated by the alternate deposition of polyarginine (pARG) and poly(ethylene glycol)-block-poly (L-aspartic acid) (PEG-b-PLD) onto an albumin conjugate. The presence of protective entanglement by polyamino acids prevented the dissociation of nab-PTX and improved its colloidal stability even at a 100-fold dilution. The combined effect of high nanoparticle internalization and controlled release of PTX from LbL-nab-PTX increased its cytotoxicity in MCF-7 and MDA-MB-231 breast cancer cells. LbL-nab-PTX consistently induced apoptosis in approximately 52% and 22% of MCF-7 and MDA-MB-231 cancer cells, respectively. LbL assembly of polypeptides effectively prevented exposure of PTX to the systemic environment and thereby inhibited drug-induced hemolysis. Most importantly, LbL assembly of polypeptides to nab-PTX effectively increased the blood circulation potential of PTX and improved therapeutic efficacy via a significantly higher area under the curve (AUC) . We report for the first time the application of LbL functional architectures for improving the systemic performance of nab-PTX with a view toward its clinical translation for cancer therapy.
[Mh] Termos MeSH primário: Paclitaxel Ligado a Albumina/química
Nanopartículas/química
[Mh] Termos MeSH secundário: Paclitaxel Ligado a Albumina/metabolismo
Paclitaxel Ligado a Albumina/farmacologia
Animais
Ácido Aspártico/química
Neoplasias da Mama/tratamento farmacológico
Linhagem Celular Tumoral
Feminino
Seres Humanos
Células MCF-7
Masculino
Polietilenoglicóis/química
Ratos
Ratos Sprague-Dawley
Distribuição Tecidual/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Albumin-Bound Paclitaxel); 30IQX730WE (Polyethylene Glycols); 30KYC7MIAI (Aspartic Acid)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170616
[Lr] Data última revisão:
170616
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170111
[St] Status:MEDLINE



página 1 de 18 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde